Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC
A Randomized Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC in Patients With Resected MAGE-A3 Positive, Stage IV Melanoma
Sponsor: GlaxoSmithKline
Terminated
Treatment Ineffective
Listed as NCT01437605, this PHASE2 trial focuses on Melanoma and remains terminated or withdrawn. Sponsored by GlaxoSmithKline, it has been updated 12 times since 2011, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 7 earlier versions
-
Jan 2020 — Jan 2021 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Apr 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE2
-
Nov 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Oct 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- H. Lee Moffitt Cancer Center and Research Institute
- Oncovir, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .